Futures for Canada’s largest market moved back up on Tuesday as data showed the inflation rate fell more than expected in June. The TSX was driven higher by gains in financial and energy stocks.

South of the border, U.S. earnings season started strong. According to analysts, of the S&P 500-listed companies that have reported, 84 per cent exceeded profit estimates.

Today in the Markets

TSX 20,376.57 +149.78 TSX
TSXV 624.41 -1.03 TSXV
CSE 158.51 -2.30 TSXV
DJIA 34,951.93 +366.58 DJIA
NASDAQ 14,353.64 +108.69 NASDAQ
S&P 500 4,554.98 +32.19 S&P 500

The Canadian dollar traded for 75.93 cents U.S., compared to 75.83 cents U.S. on Monday.

US crude futures traded $1.57 higher at $75.72 a barrel, and the Brent contract added $1.20 to $79.70 a barrel.

The price of gold was up US$23.78 to US$1,978.90.

In world markets, the Nikkei was up 102.63 points to 32,493.89, the Hang Seng was down 398.06 points to 19,015.72, the FTSE was up 47.27 points to 7,453.69, and the DAX was up 56.84 points to 16,125.49.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
An AI generated photo of a stethoscope on a computerized setting

How one company is disrupting PoC testing

When it comes to Gemina Laboratories Ltd. (CSE:GLAB), the Canada and U.K.-based company is progressing a range of PoC diagnostic technologies.
Bear and bull statues wearing Christmas hats

@ the Bell: TSX advances to start off Christmas trading week

Canada’s TSX index closed higher on Monday thanks to large-cap gains, despite weakness in real estate and telecom stocks.
Doctor with a bladder replica

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient’s Guide

As a patient with BCG-Unresponsive NMIBC CIS, bladder removal is far from the only option on the table in 2024.
Nervous system

NervGen Pharma: Proof that NVG-291 works?

Tantalizing anecdotal “evidence” has just been published suggesting that NervGen’s prospective wonder-drug, NVG-291, is delivering the goods.